Canadian Association for Pharmacy Distribution Management (CAPDM)’s Post

Pharmaceutical Pricing and Affordability in the United States: Challenges and Recommendations #healthcarereform, #globaltransformation, #healthcaretransformation, #healthpolicy, #healthcarepolicy https://lnkd.in/dcErJ6_g

#Pharmaceuticas The Ethiopian Pharmaceutical Supply Service (EPSS) is on the brink of having a new mandate that could address the country's long-standing issues with medical supply shortages. A proposed directive seeks to shift the authority for pharmaceutical procurements from the Public Procurement & Property Authority to the EPSS. The change is expected to expedite critical decision-making, ensuring a more reliable supply of essential drugs to over 420 hospitals, 4,100 health centres, and 18,500 health posts nationwide. Read more https://ow.ly/WH8850UncZa

Pharmaceutical Pricing and Affordability in the United States: Challenges and Recommendations #healthcarereform, #globaltransformation, #healthcaretransformation, #healthpolicy, #healthcarepolicy https://lnkd.in/dcErJ6_g

Improving the frameworks that govern access to new medicines is critical in bringing life saving treatments. As noted by the The Association of the British Pharmaceutical Industry (ABPI), the UK's "treatable and avoidable mortality is now the second worst in the G7 after the US, with UK mortality from treatable causes at a rate of 69 per 100,000". As we get closer to the World Evidence, Pricing and Access Congress, I'm increasingly thinking about some of these key issues and how else NICE and other HTA agencies can work together bring about the timely scheduling or appraisals for multiple therapies. You can find out more here: https://lnkd.in/eumkz8hf #patientaccess #marketaccess #pricing #reimbursement #hta #healtheconomics

At Sandoz, we believe that driving biosimilar adoption can support more equitable access to high-quality healthcare and improve outcomes for patients across the globe. We’re excited about the opportunity to foster Day 1 access to generics and biosimilars in Europe, improve supply chain resilience and simplify the regulatory framework with the ongoing EU Pharma Review 🌍 This week, Rebecca Guntern, President Region Europe and Country President Switzerland, and Peter Stenico, Global Head of Biosimilars and Country President Austria, spoke at Reuters Events Pharma where they shared their insights on the importance of revising the EU pharmaceutical legislation, regulatory streamlining, and the adoption of smarter procurement processes to increase access to generics and biosimilars in Europe. See below for some key takeaways from Rebecca and Peter 👇 #Biosimilars #Healthcare #REPharma2024 http://bit.ly/43Qc64c

New EU Health Technology Assessment Regulation starts in January 2025. Are your pharmaceutical timelines and processes ready for the streamlined clinical assessment requirements?

Adial Pharmaceuticals (NASDAQ: ADIL) has reached a key milestone in advancing AD04 for Alcohol Use Disorder. Positive results from the AD04-103 pharmacokinetics study confirm predictable bioavailability, dose proportionality, and no food effect, supporting the planned FDA 505(b)(2) pathway. These results set the stage for End-of-Phase 2 discussions and preparations for Phase 3 trials. For more: https://bit.ly/4aD9s5i #AUD #ClinicalTrials

#LegendCapital #PortfolioNews Our portfolio company, WuXi AppTec has joined the Pharmaceutical Supply Chain Initiative (#PSCI) as a Supplier Partner. This collaboration reflects WuXi AppTec’s commitment to responsible business practices and strengthening supply chain resilience by adhering to PSCI’s standards for safety, environmental, and social outcomes. WuXi AppTec’s ongoing focus on sustainability is evident in its 2024 rankings, including #1 in S&P Global’s Corporate Sustainability Assessment for Life Sciences Tools & Services, and inclusion in the Dow Jones Sustainability Indices (DJSI). The company’s integration of ESG priorities drives innovation and supports the delivery of new therapies to patients, working toward a healthier and more sustainable future. #ESG #Sustainability #Pharmaceuticals

The Canadian Association for Pharmacy Distribution Management (CAPDM), represented by CEO Angelique Berg, was invited today to appear before the House of Commons Standing Committee on Health (#HESA) to discuss the impact of #BillC64.   As the essential supply chain that ensures physical access to medications, CAPDM recommends that meaningful consultation takes place as a next step with key stakeholders including members of the pharmaceutical distribution supply chain. This is a necessary step to avoid further regulatory burden and to ensure all Canadians have safe, secure, and timely access to vital medications.   #Pharmacy #SupplyChain #PatientsFirst #CdnPoli #CdnHealth

We're pleased to announce that WuXi AppTec has joined the Pharmaceutical Supply Chain Initiative (#PSCI) as a Supplier Partner! This underscores the company’s enduring commitment to responsible business practices and supply chain resilience.   By adhering to PSCI standards and enhancing our value chain management, we remain dedicated to supporting our customers in delivering innovative new therapies to #patients, working together towards a healthier and more sustainable future.   Read more: https://lnkd.in/ejzC-esU